Medicinova Inc 10-K for FY2021

Medicinova Inc (MNOV)

10-K 2022-02-16 For: 2021-12-31

Added on April 06, 2026

About this 10-K

Medicinova Inc filed this 10-K on February 16, 2022, covering the fiscal year ended December 31, 2021 (FY2021).

Headline figures

Fiscal year ended December 31, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $4.04M
Net loss: $10.13M; compared with a net loss of $13.85M a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Delaware		33-0927979
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4275 Executive Square, Suite 300, La Jolla, CA		92037
(Address of Principal Executive Offices)		(Zip Code)

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	MNOV	The NASDAQ Stock Market LLC

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

		Page
PART I
Item 1	Business	5
Item 1A	Risk Factors	34
Item 1B	Unresolved Staff Comments	57
Item 2	Properties	57
Item 3	Legal Proceedings	57
Item 4	Mine Safety Disclosures	57

PART II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	58
Item 6	[Reserved]	58
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	59
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	62
Item 8	Financial Statements and Supplementary Data	63
Item 9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	84
Item 9A	Controls and Procedures	84
Item 9B	Other Information	85
Item 9C	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	85

PART III
Item 10	Directors, Executive Officers and Corporate Governance	86
Item 11	Executive Compensation	86
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	86
Item 13	Certain Relationships and Related Transactions, and Director Independence	87
Item 14	Principal Accountant Fees and Services	87

PART IV
Item 15	Exhibits and Financial Statement Schedules	88

Signatures		91

	•	Inability to raise additional capital if needed;
	•	Inability to generate revenues from product sales to continue business operations;
	•	Inability to develop and commercialize our product candidates;
	•	Failure or delay in completing clinical trials or obtaining FDA or foreign regulatory approval for our product candidates in a timely manner;
	•	Unsuccessful clinical trials stemming from clinical trial designs, failure to enroll a sufficient number of patients, undesirable side effects and other safety concerns;
	•	Inability to demonstrate sufficient efficacy of product candidates;
	•	Reliance on the success of our MN-166 (ibudilast) and MN-001 (tipelukast) product candidates;
	•	Delays in commencement or completion of clinical trials or suspension or termination of clinical trials;
	•	Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;
	•	Competitors may develop products rendering our product candidates obsolete and noncompetitive;
	•	The widespread outbreak of an illness or any other communicable disease, such as COVID-19, which has lead to key employees becoming ill for a period of time;
	•	Inability to successfully attract partners and enter into collaborations on acceptable terms;
	•	Dependence on third parties to conduct clinical trials and to manufacture product candidates;
	•	Dependence on third parties to market and distribute products;
	•	Our product candidates, if approved, may not gain market acceptance or obtain adequate coverage for third party reimbursement;
	•	Disputes or other developments concerning our intellectual property rights;
	•	Actual and anticipated fluctuations in our quarterly or annual operating results;

	•	Price and volume fluctuations in the overall stock markets;
	•	Litigation or public concern about the safety of our potential products;
	•	International trade or foreign exchange restrictions, increased tariffs, foreign currency exchange;
	•	High quality material for our products may become difficult to obtain or expensive;
	•	Strict government regulations on our business;
	•	Regulations governing the production or marketing of our product candidates;
	•	Loss of, or inability to attract, key personnel; and
	•	Economic, political, foreign exchange and other risks associated with international operations.

Indication	Clinical Study	Institution and Funding Agency(s)	Status

COVID-19 Primary Progressive and Secondary Progressive Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and PK of MN-166 (Ibudilast) in COVID-19 Subjects at Risk for Developing ARDS A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis	Multicenter MediciNova, Inc. Cleveland Clinic / Multicenter National Institute on Neurological Diseases and Stroke MediciNova, Inc.	Ongoing Completed

Amyotrophic Lateral Sclerosis (ALS)	A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS)	Carolinas HealthCare System Neurosciences Institute MediciNova, Inc.	Completed

ALS / Biomarker	A Biomarker Study to Evaluate MN-166 (ibudilast) in Subjects with Amyotrophic Literal Sclerosis (ALS)	Massachusetts General Hospital MediciNova, Inc.	Completed

Amyotrophic Lateral Sclerosis (ALS)	A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (ibudilast) Followed by an Open-Label Extension in Subjects with Amyotrophic Lateral Sclerosis	Multicenter MediciNova, Inc.	Ongoing

Degenerative Cervical Myelopathy	A multi-centre, double-blind, randomized, placebo-controlled trial assessing the efficacy of Ibudilast as an adjuvant treatment to decompressive surgery for degenerative cervical myelopathy	University of Cambridge / Multicenter National Institute for Health Research (NIHR) in the U.K.	Ongoing

Chemotherapy-Induced Peripheral Neuropathy	A pilot study evaluating the impact of ibudilast on prevention of chemotherapy-induced acute neurotoxicity and evaluating pharmacokinetics with oxaliplatin in gastro-intestinal cancer patients receiving oxaliplatin	University of Sydney Concord Cancer Centre in Australia	Completed
Chemotherapy-Induced Peripheral Neuropathy Glioblastoma	Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomized study Phase 1b/2a Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Efficacy of MN-166 (ibudilast) and Temozolomide Combination Treatment in Patients With Glioblastoma	University of Sydney Australasian Gastro-Intestinal Trials Group in Australia Dana-Farber Cancer Institute MediciNova, Inc.	Ongoing Ongoing
Substance Dependence / Addiction:

Methamphetamine Dependence	Randomized Trial of Ibudilast for Methamphetamine Dependence	UCLA National Institute on Drug Abuse	Completed

Methamphetamine Dependence / Biomarker	Effect of Ibudilast on Neuroinflammation in Methamphetamine Users	Oregon Health & Science University	Ongoing
Opioid Dependence	Effects of Ibudilast (MN-166), a Glial Activation Inhibitor, on Oxycodone Self-Administration in Opioid Abusers	Columbia University / NYSPI National Institute on Drug Abuse MediciNova, Inc.	Completed
Alcohol Dependence	Development of Ibudilast (MN-166) as a Novel Treatment for Alcoholism	UCLA National Institute on Alcohol Abuse and Alcoholism	Completed
Alcohol Dependence and Withdrawal Alcohol Dependence	Ibudilast (MN-166) and Withdrawal-Related Dysphoria Ibudilast (MN-166) for the Treatment of Alcohol Use Disorder	UCLA National Institute on Drug Abuse UCLA National Institute on Alcohol Abuse and Alcoholism	Completed Ongoing

	Year Ended December 31,
	2021		2020
External development expense:
MN-221	$	11	$	2
MN-166		5,962		4,250
MN-001		192		197
MN-029		3		3
Other		28		240
Total external development expense		6,196		4,692
R&D personnel expense		1,378		2,149
R&D facility and depreciation expense		47		47
Patent expense		438		357
Other R&D expense		479		240
Total research, development and patent expense	$	8,538	$	7,485

	2021			2020
Net cash (used in) provided by:
Operating activities		(9,382	)		(10,826	)
Investing activities		(29	)		(36	)
Financing activities		20,778			7,106
Total	$	11,367		$	(3,756	)

		Page
Reports of Independent Registered Public Accounting Firm (BDO USA, LLP; San Diego, California; PCAOB ID#243)		64
Financial Statements:
Consolidated Balance Sheets		66
Consolidated Statements of Operations and Comprehensive Loss		67
Consolidated Statements of Stockholders’ Equity		68
Consolidated Statements of Cash Flows		69
Notes to Consolidated Financial Statements		70

	December 31,
	2021			2020
Assets:
Current assets:
Cash and cash equivalents	$	71,430,954		$	60,036,763
Prepaid expenses and other current assets		577,992			680,171
Total current assets		72,008,946			60,716,934
Goodwill		9,600,240			9,600,240
In-process research and development		4,800,000			4,800,000
Property and equipment, net		57,565			55,700
Right-of-use asset		824,215			170,857
Other non-current assets		115,492			75,379
Total assets	$	87,406,458		$	75,419,110
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	402,740		$	616,629
Accrued liabilities and other current liabilities		2,298,203			1,391,293
Operating lease liability		131,965			186,028
Total current liabilities		2,832,908			2,193,950
Long-term deferred revenue		—			1,694,163
Deferred tax liability		201,792			201,792
Other non-current liabilities		694,674			2,705
Total liabilities		3,729,374			4,092,610
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2021 and December 31, 2020; 49,043,246 and 45,024,560 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively		49,043			45,025
Additional paid-in capital		476,788,012			454,296,536
Accumulated other comprehensive loss		(98,877	)		(88,219	)
Accumulated deficit		(393,061,094	)		(382,926,842	)
Total stockholders’ equity		83,677,084			71,326,500
Total liabilities and stockholders’ equity	$	87,406,458		$	75,419,110

	Years ended December 31,
	2021			2020
Revenues	$	4,037,500		$	—
Operating expenses:
Research, development and patents		8,538,027			7,484,835
General and administrative		5,715,285			6,693,488
Total operating expenses		14,253,312			14,178,323
Operating loss		(10,215,812	)		(14,178,323	)
Interest income		143,626			361,182
Other expense, net		(59,498	)		(38,404	)
Loss before income taxes		(10,131,684	)		(13,855,545	)
Income tax benefit (expense)		(2,568	)		1,648
Net loss applicable to common stockholders	$	(10,134,252	)	$	(13,853,897	)
Basic and diluted net loss per common share	$	(0.21	)	$	(0.31	)
Shares used to compute basic and diluted net loss per common share		48,596,255			44,413,441
Net loss applicable to common stockholders	$	(10,134,252	)	$	(13,853,897	)
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments		(10,658	)		4,462
Comprehensive loss	$	(10,144,910	)	$	(13,849,435	)

	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Shares		Amount		capital		loss			deficit			equity
Balance at December 31, 2019		43,908,065	$	43,908	$	444,016,341	$	(92,681	)	$	(369,072,945	)	$	74,894,623
Share-based compensation		—		—		3,175,553		—			—			3,175,553
Issuance of shares under an employee stock purchase plan (ESPP)		3,834		4		11,704		—			—			11,708
Issuance of common stock under at-the-market equity distribution and sales agreements, net of offering costs		824,798		825		6,187,254		—			—			6,188,079
Issuance of common stock for option exercises		287,863		288		905,684		—			—			905,972
Net loss		—		—		—		—			(13,853,897	)		(13,853,897	)
Foreign currency translation adjustments		—		—		—		4,462			—			4,462
Balance at December 31, 2020		45,024,560		45,025		454,296,536		(88,219	)		(382,926,842	)		71,326,500
Share-based compensation		—		—		1,717,513		—			—			1,717,513
Issuance of shares under an employee stock purchase plan (ESPP)		1,424		2		6,108		—			—			6,110
Issuance of common stock in a private placement transaction, net of issuance costs		3,656,307		3,656		19,877,976		—			—			19,881,632
Issuance of common stock for option exercises		360,955		360		889,879		—			—			890,239
Net loss		—		—		—					(10,134,252	)		(10,134,252	)
Foreign currency translation adjustments		—		—		—		(10,658	)		—			(10,658	)
Balance at December 31, 2021		49,043,246	$	49,043	$	476,788,012	$	(98,877	)	$	(393,061,094	)	$	83,677,084

Level 1:		Observable inputs such as quoted prices in active markets;

Level 2:		Inputs are quoted prices for similar items in active markets or inputs are quoted prices for identical or similar items in markets that are not active near the measurement date; and

Level 3:		Unobservable inputs due to little or no market data, which require the reporting entity to develop its own assumptions

	Year Ended December 31,
	2021			2020

Cash paid for operating lease liabilities	$	242,676		$	248,648
Operating lease costs		228,779			240,467
Right-of-use assets obtained in exchange for new operating lease obligations		870,373			—

Current operating lease liabilities	$	131,965		$	186,028
Non-current operating lease liabilities		694,674			2,705
Total operating lease liabilities	$	826,639		$	188,733

Weighted-average remaining lease term		4.54			0.86
Weighted-average discount rate		9.8	%		8.8	%

Maturities of operating lease liabilities as of December 31, 2021 were as follows:
2022	$	210,816
2023		221,104
2024		189,170
2025		197,586
2026		206,483
Thereafter		17,269
Total minimum payments	$	1,042,428
Less imputed interest		(215,789	)
Total lease liabilities	$	826,639

	Number of Option Shares			Weighted Average Exercise Price
Outstanding at December 31, 2019		6,802,093		$	5.61
Granted		1,382,000		$	6.67
Exercised		(287,863	)	$	3.15
Cancelled		(494,843	)	$	8.73
Outstanding at December 31, 2020		7,401,387		$	5.70
Granted		1,315,000		$	5.82
Exercised		(360,955	)	$	2.47
Cancelled		(381,182	)	$	6.77
Outstanding at December 31, 2021		7,974,250		$	5.81
Exercisable at December 31, 2021		6,687,917		$	5.81

	Number of Option Shares			Weighted Average Grant-Date Fair Value
Non-vested at December 31, 2020		1,280,500		$	3.74
Granted		1,315,000		$	3.51
Vested		(1,133,167	)	$	3.70
Forfeitures		(176,000	)	$	3.81
Non-vested at December 31, 2021		1,286,333		$	3.54

	Year Ended December 31,
Current:	2021			2020
Federal	$	—		$	—
State		—			—
Foreign		(2,568	)		1,648
Total current income tax benefit (expense)		(2,568	)		1,648
Deferred:
Federal		—			—
State		—			—
Foreign		—			—
Total deferred income tax benefit (expense)		—			—
Total income tax benefit (expense)	$	(2,568	)	$	1,648

	Year Ended December 31,
Deferred tax assets:	2021			2020
Net operating loss carryforwards	$	68,485,037		$	67,403,329
Capitalized licenses		30,784			98,411
Research tax credits		9,262,071			8,980,935
Stock options		1,601,862			2,902,963
Other, net		423,279			770,100
Right-of-use asset		196,059			39,615
Total deferred tax assets		79,999,092			80,195,353
Deferred tax liabilities
Right-of-use liability		(196,059	)		(35,726	)
In process R&D		(1,343,213	)		(1,343,213	)
Total deferred tax liabilities		(1,539,272	)		(1,378,939	)
Net deferred tax assets		78,459,820			78,816,414
Valuation allowance		(78,661,612	)		(79,018,206	)
Net deferred tax liability	$	(201,792	)	$	(201,792	)

		Page
Report of Independent Registered Public Accounting Firm		64
Consolidated Balance Sheets		66
Consolidated Statements of Operations and Comprehensive Loss		67
Consolidated Statements of Stockholders’ Equity		68
Consolidated Statements of Cash Flows		69
Notes to Consolidated Financial Statements		70

Exhibit Number		Description

3.1		Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed August 9, 2012).

3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-119433) filed October 1, 2004).

4.1		Specimen of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K (File No. 001-33185) filed February 15, 2007).

4.2		Amended and Restated Registration Rights Agreement, dated September 2, 2004, by and among the Registrant, its founders and the investors named therein (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-119433) filed October 1, 2004).

4.3		Description of Capital Stock

10.1*		Amended and Restated 2004 Stock Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-33185) filed March 29, 2012).

10.2*		Form of Indemnity Agreement between the Registrant and its officers and directors (incorporated by reference to Exhibit 10.3 of the Registrant’s Annual Report on Form 10-K (File No. 001-33185) filed March 28, 2013).

10.3†		License Agreement, dated March 14, 2002, between the Registrant and Kyorin Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-119433), originally filed on October 1, 2004).

10.4†		License Agreement, dated June 19, 2002, between the Registrant and Angiogene Pharmaceuticals, Ltd. (incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-119433), originally filed on October 1, 2004).

10.5†		Exclusive License Agreement, dated February 25, 2004, between the Registrant and Kissei Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-119433), originally filed on October 1, 2004).

10.6†		License Agreement, dated October 22, 2004, between the Registrant and Kyorin Pharmaceutical Co., Ltd., (incorporated by reference to Exhibit 10.18 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-119433), originally filed on October 1, 2004).

10.7†		License Agreement, dated October 31, 2006, by and between the Registrant and Meiji Seika Kaisha, Ltd. (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 000-51133) filed November 2, 2006).

Exhibit Number		Description

10.8†		License Agreement, dated October 31, 2006, by and between the Registrant and Meiji Seika Kaisha, Ltd. (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K (File No. 000-51133) filed November 2, 2006).

10.9*		Executive Employment Agreement, dated April 1, 2007, between the Registrant and Yuichi Iwaki, M.D., Ph.D. (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed April 4, 2007).

10.10*		2007 Employee Stock Purchase Plan of the Registrant (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A (File No. 001-33185) filed March 13, 2007).

10.11†		Development and Supply Agreement, dated as of March 26, 2009, between the Registrant and Hospira Worldwide, Inc. (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed March 30, 2009).

10.12†		Assignment Agreement, dated December 19, 2005, between Genzyme Corporation and Avigen, Inc. (incorporated by reference to Exhibit 10.58 of Avigen, Inc.’s Annual Report on Form 10-K (File No. 000-51133) filed February 16, 2006).

10.13†		Asset Purchase Agreement, dated December 17, 2008, between Baxter Healthcare Corporation, Baxter International Inc., and Baxter Healthcare S.A. and Avigen, Inc. (incorporated by reference to Exhibit 2.2 of Avigen, Inc.’s Annual Report on Form 10-K (File No. 001-33185) filed March 31, 2009).

10.14*		Form of Amendment to Employment Agreement, dated December 31, 2011, between the Registrant and Yuichi Iwaki, M.D., Ph.D. (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed January 4, 2011).

10.15		Sublease, by and between MediciNova, Inc. and Cardinal Health 127 Inc., dated August 31, 2017 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K (File No. 001-33185) filed with the SEC on September 7, 2017).

10.16*		2013 Equity Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.23 of the Registrant’s Annual Report on Form 10-K (File No. 001-33185) filed March 27, 2014).

10.17*		Amended and Restated 2013 Equity Incentive Plan of the Registrant.* (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed July 26, 2017).

10.18*		Form of Notice of Stock Option Grant and Stock Option Agreement for awards pursuant to the 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed November 7, 2013).

10.19*		Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Dr. Yuichi Iwaki (incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed August 13, 2014).

10.20*		Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Dr. Kazuko Matsuda (incorporated by reference to Exhibit 10.4 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed August 13, 2014).

10.21*		Severance Protection Agreement, dated July 14, 2014, by and between MediciNova, Inc. and Geoffrey O’Brien (incorporated by reference to Exhibit 10.5 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33185) filed August 13, 2014).

10.22		At Market Issuance Sales Agreement, dated August 23, 2019, by and between MediciNova, Inc. and B. Riley FBR, Inc. (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed August 23, 2019). Inc.

10.23		Securities Purchase Agreement, dated January 11, 2021, between the Company and 3D Opportunity Master Fund (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed January 12, 2021.

10.24		Shareholder Rights Agreement, dated January 11, 2021, between the Company and 3D Opportunity Master Fund (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed January 12, 2021.

Exhibit Number		Description

10.25		Services Agreement, dated August 1, 2021, by and between MediciNova, Inc. and Signature Analytics LLC (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed August 2, 2021.

10.26		Lease, dated July 20, 2021, by and between MediciNova, Inc. and the Irvine Company LLC (incorporated by reference to Exhibit 99.1 of the Registrant’s Current Report on Form 8-K (File No. 001-33185) filed July 23, 2021.

23.1		Consent of Independent Registered Public Accounting Firm.

24.1		Powers of Attorney (see signature page).

31.1		Certification of the Principal Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Act of 1933.

31.2		Certification of the Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Act of 1933.

32.1		Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements from MediciNova, Inc. on Form 10-K as of and for the year ended December 31, 2021 formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Comprehensive Loss; (iii) Consolidated Statements of Stockholders’ Equity; (iv) Consolidated Statements of Cash Flows; and (v) the notes to the consolidated financial statements.

	MEDICINOVA, INC.
	A Delaware Corporation

Date: February 16, 2022	By:	/s/ Yuichi Iwaki
		Yuichi Iwaki, M.D., Ph.D.
		President & Chief Executive Officer

Signature	Title	Date

/s/ Yuichi Iwaki Yuichi Iwaki, M.D., Ph.D.	Director, President and Chief Executive Officer (Principal executive officer)	February 16, 2022

/s/ Douglas Paulin Douglas Paulin	Chief Financial Officer (Principal financial and accounting officer)	February 16, 2022

/s/ Jeff Himawan Jeff Himawan, Ph.D.	Chairman of the Board of Directors	February 16, 2022


/s/ Carolyn Beaver Carolyn Beaver	Director	February 16, 2022

/s/ Kazuko Matsuda Kazuko Matsuda	Director	February 16, 2022
/s/ Hideki Nagao Hideki Nagao	Director	February 16, 2022